Table 4.
Subgroup analysis of VTE and other adverse events by prophylaxis type for ISS>15.
| Patients (N) | VTE Prophylaxis Agent |
P-value | ||
|---|---|---|---|---|
| UH (%) | LMWH (%) | |||
| Outcome | ||||
| VTE (PE or DVT) | 53 | 18 (18.8) | 35 (7.4) | 0.0017 |
| PE | 20 | 8 (8.3) | 12 (2.6) | 0.012 |
| DVT | 41 | 13 (13.5) | 28 (6) | 0.016 |
| ARDS | 19 | 2 (2.1) | 17 (3.6) | 0.755 |
| Cardiac arrest | 8 | 3 (3.1) | 5 (1.1) | 0.141 |
| MI | 2 | 1 (1) | 1 (0.2) | 0.314 |
| Stroke/CVA | 3 | 0 (0) | 3 (0.6) | 1.000 |
| Unplanned Intubation | 17 | 4 (4.2) | 13 (2.8) | 0.509 |
| Bleed Event | 0 | 0 (0) | 0 (0) | 1.000 |
| Any complication | 90 | 26 (27.1) | 64 (13.6) | 0.0021 |
| Death | 7 | 4 (4.2) | 3 (0.6) | 0.0181 |
| Hospital Length of Stay (Days) | 0.026 | |||
| 1 to 4 | 39 | 3 (3.1) | 36 (7.7) | |
| 5 to 9 | 193 | 25 (26) | 168 (35.7) | |
| 10 or greater | 333 | 68 (70.8) | 265 (56.4) | |
| ICU length of stay (Days) | 0.067 | |||
| 1 to 4 | 154 | 21 (21.9) | 133 (28.3) | |
| 5 to 9 | 116 | 22 (22.9) | 94 (20) | |
| 10 or greater | 150 | 36 (37.5) | 114 (24.3) | |
†Significant P-values are defined as <0.05/12 = 0.0041 after Bonferroni correction and are presented in bold.
ISS: Injury Severity Scale, VTE: venous thromboembolism, UH: unfractionated heparin, LMWH: low molecular weight heparin, DVT: deep vein thrombosis, PE: pulmonary embolism, ARDS: acute respiratory distress syndrome, MI: myocardial infarction, CVA: cerebrovascular accident.